Compounding HRT Solutions for Healthy Aging Patients

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, in the context of age-related hormonal change, maintained mobility may present as preserved ability to walk, climb stairs, and perform daily tasks independently, reflecting adequate muscle strength, balance, and joint flexibility. A steady, energetic gait, minimal pain or stiffness, and sustained endurance may support independence and safe navigation of daily activities. Adequate proprioception and reaction time may contribute to confident movement and reduced fall risk. Patients experiencing significant decline in mobility — such as sudden weakness, frequent falls, or inability to perform basic tasks — should seek prompt evaluation from a qualified clinician, as these symptoms may indicate an underlying condition requiring diagnosis and management.

According to NIH MedlinePlus and NAMS (The Menopause Society), preserved cognitive function in the context of healthy aging may present as the ability to concentrate, retain new information, recall details, and manage complex tasks without significant difficulty. Cognitive changes associated with hormonal shifts may include reduced processing speed, mild memory lapses, or difficulty with attention and word retrieval. These symptoms may vary in severity and may worsen with sleep disruption or mood disturbance. Patients experiencing notable or rapid cognitive decline — such as confusion, disorientation, or significant memory impairment — should seek evaluation from a qualified clinician, as such symptoms may indicate a condition requiring medical assessment.

According to NIH MedlinePlus and NAMS (The Menopause Society), shifts in emotional well-being during hormonal change may present as sudden mood swings, increased irritability, low-grade anxiety, episodes of tearfulness, decreased motivation, difficulty concentrating, and a sense of emotional numbness or heightened sensitivity. Sleep disruption and fatigue may worsen these symptoms, affecting daily function and relationships. Episodes may vary in intensity and duration, sometimes impacting work and social life. Patients experiencing persistent or severe mood changes — particularly those accompanied by thoughts of self-harm — should seek evaluation from a qualified clinician promptly, as these symptoms may indicate a condition requiring clinical assessment and management.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, a gradual loss of independence in daily activities may present as increasing difficulty with activities of daily living: managing personal care, bathing, dressing, toileting, and feeding; preparing meals, housekeeping, shopping, and handling finances. Slowed or unsteady mobility, reduced stamina, greater fatigue, missed medications, and need for reminders or supervision may also be observed. Subtle cognitive lapses affecting planning and decision-making, often with increased reliance on others, may accompany these changes. Patients experiencing sudden or rapidly worsening loss of function should seek evaluation from a qualified clinician, as these symptoms may indicate a condition requiring prompt medical assessment.

According to the FDA-approved prescribing information for Prometrium, Prometrium is an oral micronized progesterone indicated as a progestogen component of menopausal hormone therapy in women with a uterus, to reduce the incidence of endometrial hyperplasia that may be induced by estrogen. The labeling describes that Prometrium mimics the activity of endogenous progesterone and may protect the endometrium from estrogen-stimulated proliferation. Per the labeling, Prometrium may be associated with risks including venous thromboembolism, breast cancer (with prolonged combination estrogen-progestogen use), cardiovascular events, and central nervous system effects such as dizziness and somnolence; patients should be monitored regularly. Any compounded preparation involving progesterone is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Prometrium products are separately regulated, and clinical decisions regarding its use belong with the prescribing clinician.

According to the FDA-approved prescribing information for Vivelle-Dot, Vivelle-Dot is a transdermal 17β-estradiol patch applied twice weekly, indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, symptoms of vulvar and vaginal atrophy associated with menopause, hypoestrogenism due to hypogonadism, castration, or primary ovarian insufficiency, and prevention of postmenopausal osteoporosis. The labeling describes that Vivelle-Dot delivers estradiol through intact skin to systemic circulation, avoiding first-pass hepatic metabolism associated with oral estrogen administration. Per the labeling, Vivelle-Dot carries an FDA Boxed Warning noting that estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia; the labeling describes increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis. Use at the lowest effective dose for the shortest duration consistent with treatment goals is described in the labeling. Any compounded preparation involving transdermal estradiol is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Vivelle-Dot products are separately regulated, and clinical decisions regarding its use belong with the prescribing clinician.